Searched for
BI SPECIFIC ANTIBODIES
Glenmark’s blood cancer drug ISB 2001 shows promising results in trialIchnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating...- J&J acquires experimental skin disorder drug for $1.25 billionNUMAB THERAPEUTICS-JOHNSON&JOHNSON/M&A (UPDATE 2, PIX)UPDATE 2-J&J acquires experimental skin disorder drug for $1.25 billion
- Roche launches top selling eye drug Vabysmo in IndiaRoche Pharma India launches Vabysmo, a medication for neovascular age-related macular degeneration and diabetic macular edema in India. The...
- India deal activity to remain on upward trend: ReportIndia is expected to see an upward trajectory in deal activity in 2024, according to a report by Bain & Company's Global Healthcare Private...
- Glenmark bets on respiratory drug, licensing deals to improve businessGlenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...
- Amid Covid vaccine success, BioNTech plans to return €2bn to shareholdersAfter the success of the covid vaccine, BioNTech is planning to return €2bn to shareholders. BioNTech will continue the clinical trial to b...
- SPARC enters licensing pact with Biomodifying for licensing of novel drug targets against cancer“This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPAR...
- Ideas to Innovation series: In conversation with the EY Entrepreneur of the Year Award Winner 2017 (Part 6)Exclusive interview with Sunder Genomal, Managing Director, Page Industries and Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals
- Glenmark readies specialty, innovative pipeline as pricing challenges loom in the USGlenmark’s consolidated net profit saw a deep cut, dropping 78 per cent to Rs. 104.7 crore.
- Glenmark Pharmaceuticals starts studies on new drug aimed at cancer treatmentShares of Glenmark Pharmaceuticals were trading at Rs 867 in the afternoon trade, up 0.05 per cent from the previous close on BSE.
- Glenmark's novel antibody GBR 1302 to enter clinical trialsGlenmark has completed the pre-clinical evaluation for its bi-specific antibody GBR 1302 and filed the phase I trial application for the sa...
- Budget 2011: Finance Bill 2011A BILL to give effect to the financial proposals of the Central Government for the financial year 2011-2012. Be it enacted by Parliament in...
Load More
